全球黃熱病治療市場規模、份額和趨勢分析報告—產業概覽和 2032 年預測

 黃熱病治療市場規模

• 2024 年全球黃熱病治療市場規模為5.2772 億美元 ，預計 到 2032 年將達到 7.1668 億美元，預測期內 複合年增長率為 3.90%。
• 市場成長很大程度上得益於疫苗開發和媒介控制策略的日益普及和技術進步，從而提高了流行地區和非流行地區的免疫覆蓋率。
• 此外，全球對旅遊相關健康風險的認識不斷提高，以及對有效、持久和易於獲得的疫苗的需求，使得黃熱病疫苗成為預防性醫療保健解決方案的基石。這些因素共同加速了黃熱病疫苗接種計劃的實施，從而顯著促進了該行業的發展。

黃熱病治療市場分析

• 黃熱病疫苗能夠有效預防黃熱病病毒，由於其療效確切、保護時間長、在疫情防治中發揮關鍵作用，已成為黃熱病流行區和非流行區公共衛生舉措和國際旅行法規中日益重要的組成部分。
• 黃熱病疫苗需求不斷增長，主要原因是媒介傳播疾病發病率上升、前往高風險地區的國際旅行增加，以及政府和非政府為擴大弱勢群體的免疫覆蓋率而做出的努力不斷增加。
• 非洲在黃熱病市場佔據主導地位，2025 年其收入份額最大，為 47.6%，其特點是疾病負擔高、免疫接種運動強勁、並得到全球衛生組織的支持，尼日利亞和剛果民主共和國等國家的疫苗接種率大幅增長，特別是通過大規模免疫接種運動和綜合疾病監測計劃。
• 由於最近疫情爆發、旅行者疫苗接種要求的加強以及公共衛生基礎設施的加強，預計拉丁美洲將成為預測期內黃熱病市場成長最快的地區。
• 減毒活疫苗預計將在黃熱病市場佔據主導地位，到 2025 年，其市場份額將達到 69.4%，這得益於其長期使用、高效性以及世界衛生組織 (WHO) 認可其作為黃熱病的主要預防措施

報告範圍和黃熱病治療市場細分      

黃熱病治療市場趨勢

“透過人工智慧和預測性監控增強預防”

• A significant and accelerating trend in the global yellow fever market is the deepening integration of artificial intelligence (AI) and predictive analytics into disease surveillance, vaccine distribution, and outbreak response systems. This fusion of technologies is significantly enhancing the efficiency and effectiveness of global yellow fever prevention strategies.
  • For instance, AI-driven platforms developed by health tech firms and research institutions are being used to model outbreak patterns, identify high-risk regions, and optimize the allocation of limited vaccine supplies. Similarly, AI-based geographic information systems (GIS) help map mosquito population density and environmental risk factors, providing data-driven insights for targeted vaccination campaigns.
• AI integration in yellow fever management enables features such as real-time monitoring of epidemiological data, early detection of outbreak signals, and improved forecasting of transmission dynamics. For example, predictive models developed by global health agencies can anticipate outbreaks weeks in advance, allowing for timely interventions and deployment of medical resources. Furthermore, machine learning algorithms are being employed to analyze vaccine efficacy and adverse event patterns across diverse populations.
•  The seamless integration of AI with public health infrastructure and digital health records facilitates centralized control over disease tracking, vaccination coverage, and response planning. Through a unified data platform, health authorities can manage yellow fever cases alongside other vector-borne diseases, ensuring a coordinated and proactive approach to public health.
• This trend towards more intelligent, responsive, and data-driven disease control systems is fundamentally reshaping how governments and organizations prepare for and mitigate yellow fever outbreaks. Consequently, companies and institutions such as IBM Watson Health and the World Health Organization are investing in AI-enabled surveillance networks that can rapidly assess risk and guide vaccination strategies.
• The demand for AI-powered tools that support early detection, predictive planning, and smart resource allocation is growing rapidly across both developed and developing regions, as public health agencies increasingly prioritize advanced technologies for epidemic preparedness and control.

Yellow fever treatment Market Dynamics

Driver

“Growing Need Due to Rising Outbreak Risks and Global Travel”

• The increasing prevalence of yellow fever outbreaks in endemic regions, coupled with the rising volume of international travel to high-risk areas, is a significant driver for the heightened demand for yellow fever vaccines and surveillance programs.
  •  For instance, in March 2024, the World Health Organization (WHO), in collaboration with Gavi and UNICEF, expanded its EYE (Eliminate Yellow fever Epidemics) strategy to cover additional countries in Africa and South America, aiming to strengthen outbreak response capacity and vaccination coverage. Such strategies by global health organizations are expected to drive the yellow fever market growth in the forecast period.
• As populations and travelers become more aware of vector-borne disease threats and the need for preventive healthcare, yellow fever vaccines offer critical protection through long-lasting immunity and global recognition as a required travel vaccine.
• Furthermore, the resurgence of yellow fever in previously low-risk regions and the ongoing threat of urban transmission are making robust immunization programs and surveillance systems an integral part of public health planning, especially in tropical and subtropical zones.
• The requirement of yellow fever vaccination for travel to certain countries, government-led immunization campaigns, and global stockpile initiatives are key factors propelling the demand for yellow fever vaccines in both endemic and non-endemic regions. The increased availability of WHO-prequalified vaccines and investments in domestic manufacturing by emerging economies further contribute to market growth

Restraint/Challenge

“Concerns Regarding Vaccine Supply, Efficacy, and Accessibility”

• Concerns surrounding limited vaccine supply, uneven distribution infrastructure, and variable efficacy in certain populations pose a significant challenge to broader yellow fever vaccine coverage. As yellow fever outbreaks often occur in resource-limited regions, logistical barriers such as cold chain requirements, remote geography, and inadequate healthcare infrastructure hinder timely and widespread immunization efforts.
  • For instance, past outbreaks in Africa and South America have highlighted gaps in vaccine availability, with demand outpacing supply during emergency situations, leading to the use of fractional dosing strategies as a temporary measure.
• Addressing these challenges through investments in local vaccine manufacturing, improved global stockpile management, and coordinated distribution networks is crucial for ensuring equitable access. Organizations such as Gavi and the WHO have emphasized the need for regional production facilities and stronger surveillance systems to support rapid response. Additionally, concerns about vaccine-related adverse effects, although rare, can lead to vaccine hesitancy among certain populations, especially when misinformation spreads through social or traditional media.
• While the yellow fever vaccine is highly effective, some individuals—such as the elderly or those with weakened immune systems—may face contraindications, limiting their eligibility and posing a challenge for mass immunization strategies.
• Overcoming these challenges through expanded education on vaccine safety, diversification of supply sources, and improved healthcare infrastructure in endemic regions will be vital for sustained market growth.

Yellow fever treatment Market Scope

The market is segmented on the basis transmission type, treatment type, medication type, Route of administration, end user and distribution channels

By Transmission Type

On the basis of transmission type, the global yellow fever market is segmented into sylvatic yellow fever, intermediate yellow fever, urban yellow fever, and others. The sylvatic yellow fever segment dominates the largest market revenue share of 45.1% in 2025, driven by its prevalence in forested areas where the primary vector, Aedes mosquitoes, thrives. This type of yellow fever is more common in regions of Africa and South America, where outbreaks often occur in rural and remote areas. The sylvatic cycle is particularly concerning due to its potential to spill over into urban areas, prompting vaccination campaigns and surveillance efforts in at-risk regions.

The urban yellow fever segment is anticipated to witness the fastest growth rate of 19.3% from 2025 to 2032, fueled by increasing urbanization in tropical areas where mosquito vectors are expanding their range. Urban yellow fever poses a greater public health risk due to the higher population density and mobility, making it easier for the disease to spread rapidly. The rise in international travel also contributes to the increased risk of urban outbreaks, prompting countries to implement stricter vaccination protocols and preventive measures in metropolitan areas. The growing awareness of the need for urban surveillance systems and vaccination requirements for travelers is also boosting demand for urban yellow fever vaccination.

By Treatment Type

On the basis of treatment type, the global yellow fever market is segmented into vaccination, medication, and others. The vaccination segment dominates the largest market revenue share of 62.4% in 2025, driven by its critical role in the prevention of yellow fever outbreaks. Yellow fever vaccines, particularly the live-attenuated vaccine, are considered the gold standard in preventing the disease, offering long-term immunity with a single dose. The widespread use of yellow fever vaccination programs by global health organizations, such as the WHO and Gavi, significantly contributes to this segment's dominance. Additionally, the requirement for yellow fever vaccination for travel to certain high-risk countries further boosts demand for vaccines.

The medication segment is anticipated to witness the fastest growth rate of 15.8% from 2025 to 2032, primarily due to advancements in supportive care and symptom management. Although there is no specific antiviral treatment for yellow fever, the use of supportive care, such as antipyretics for fever management and medications to manage complications like bleeding and organ failure, is critical in improving patient outcomes. Research into novel therapies is also expected to drive this segment’s growth, particularly in the treatment of severe yellow fever cases.

By Medication Type

On the basis of medication type, the global yellow fever market is segmented into histamine H2 antagonists, proton pump inhibitors, antipyretics, and others. The antipyretics segment dominates the largest market revenue share of 38.5% in 2025, driven by its critical role in managing fever, one of the most common and uncomfortable symptoms of yellow fever. Antipyretics, such as acetaminophen, are widely used to reduce fever and improve patient comfort during the acute phase of the disease. The prevalence of fever as a primary symptom in yellow fever patients, coupled with the global focus on symptom management, strengthens the demand for antipyretic medications.

The proton pump inhibitors (PPIs) segment is expected to witness the fastest growth rate of 17.2% from 2025 to 2032, fueled by the increasing recognition of gastrointestinal complications in severe cases of yellow fever. PPIs are used to manage ulcers and gastrointestinal bleeding, which can occur in more severe yellow fever cases. With growing awareness of these complications, especially in areas where yellow fever is prevalent, the demand for proton pump inhibitors is expected to rise, further expanding the medication type segment.

By Route of Administration

On the basis of route of administration, the global yellow fever market is segmented into oral, injectable, and others. The injectable segment dominates the largest market revenue share of 79.6% in 2025, driven by the widespread use of the yellow fever vaccine, which is administered via injection. The injectable form is the preferred method for yellow fever vaccination due to its proven efficacy and long-lasting immunity with a single dose. The global push for vaccination, particularly in high-risk areas and for travelers to endemic regions, significantly contributes to the dominance of the injectable segment.

The oral segment is anticipated to witness the fastest growth rate of 12.3% from 2025 to 2032, fueled by ongoing research into alternative vaccine delivery systems. Oral vaccines offer potential benefits in terms of ease of administration, particularly in mass vaccination campaigns, and may help overcome logistical barriers in remote or under-resourced regions. As vaccine developers explore and test oral vaccine formulations, the demand for oral vaccines in yellow fever prevention is expected to grow in the coming years.

Yellow fever treatment market Regional Analysis

• Africa dominates the global yellow fever market with the largest revenue share of 45.2% in 2025, driven by the high incidence of yellow fever outbreaks in endemic regions and the critical role of vaccination programs.
• Consumers and governments in the region highly prioritize vaccination campaigns, public health education, and disease surveillance efforts to curb the spread of yellow fever. International health organizations, such as the WHO, play a pivotal role in supporting vaccination efforts and outbreak response in Africa.
• This widespread demand for yellow fever prevention is further supported by regional collaborations, increased funding for immunization programs, and the implementation of mass vaccination campaigns, establishing yellow fever vaccines as a primary tool for combating the disease in both rural and urban areas.

Africa Yellow fever treatment Market Insight

The Africa yellow fever market captured the largest revenue share of 85% within the global market in 2025, fueled by the high incidence of yellow fever outbreaks in endemic regions and the critical role of vaccination programs. Governments and international health organizations are prioritizing the prevention and control of yellow fever through mass vaccination campaigns, particularly in high-risk areas. The increasing focus on strengthening healthcare infrastructure, alongside efforts to expand vaccination coverage, further propels the yellow fever market. Moreover, the growing collaboration between the World Health Organization (WHO), Gavi, and local governments is significantly contributing to the market's expansion, with a focus on increasing access to vaccines and improving outbreak response capabilities across the continent.

U.S. Yellow fever treatment Market Insight

The U.S. yellow fever market captured the largest revenue share of 45% within North America in 2025, driven by the high demand for yellow fever vaccinations, particularly for travelers visiting endemic regions. The growing awareness among U.S. travelers about the risks of yellow fever and the importance of vaccination before traveling to countries with active outbreaks contributes to the strong market presence. The increasing need for preventive measures in international travel, along with government regulations requiring vaccination for entry into certain high-risk countries, is further boosting the market. Moreover, partnerships between the U.S. government, pharmaceutical companies, and international health organizations are playing a key role in expanding vaccination availability and ensuring timely access to vaccines.

U.K. Yellow fever treatment Market Insight

The U.K. yellow fever market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by the increasing number of travelers to endemic regions and the growing awareness about the importance of yellow fever vaccination. As more U.K. residents travel to Africa and South America, where yellow fever remains a risk, the demand for vaccination is expected to rise. Additionally, the U.K.'s robust healthcare infrastructure and collaboration with global health organizations, such as the WHO, are encouraging preventive measures and vaccination campaigns. The country’s established healthcare systems, coupled with a high level of awareness regarding travel-related health risks, are expected to continue to stimulate market growth.

Germany Yellow fever treatment Market Insight

The German yellow fever market is expected to expand at a considerable CAGR during the forecast period, fueled by the rising volume of international travel to yellow fever-endemic regions and growing awareness of travel-related health precautions. Germany’s strong public health infrastructure, combined with its emphasis on preventive healthcare, supports the consistent demand for yelloww fever vaccination among outbound travelers. The integration of digital health records and appointment systems has made access to travel vaccines more streamlined and efficient. Additionally, German consumers exhibit a strong preference for regulated, safety-focused medical solutions, aligning with government vaccination recommendations and international travel requirements.  

Asia-Pacific Yellow fever treatment Market Insight

The Asia-Pacific yellow fever market is poised to grow at the fastest CAGR of over 21% in 2025, driven by the increasing number of outbound travelers to yellow fever-endemic regions and rising awareness of international vaccination requirements. Countries such as China, Japan, and India are witnessing growing demand for yellow fever vaccines, primarily due to expanding international travel for business, tourism, and education. Government efforts to strengthen travel health services and promote preventive care are also supporting market growth. Furthermore, the region’s role in pharmaceutical manufacturing and the development of cost-effective vaccine solutions is improving vaccine accessibility and encouraging proactive immunization among traveler.  

Japan Yellow fever treatment Market Insight

The Japan yellow fever market is gaining momentum due to the country’s strong focus on preventive healthcare, high international travel volume, and compliance with global vaccination requirements. Japanese travelers frequently visit yellow fever-endemic regions, prompting a steady demand for certified yellow fever vaccination. The market is further supported by Japan’s well-developed healthcare infrastructure and its emphasis on public health awareness. Additionally, the aging population and a growing preference for precautionary health measures are likely to spur demand for accessible and efficient vaccination services, particularly for those at higher risk when traveling abroad.  

China Yellow fever treatment Market Insight

The China yellow fever market accounted for the largest market revenue share in Asia Pacific in 2025, attributed to the country’s growing outbound travel sector, rising middle class, and heightened awareness of international vaccination requirements. As one of the world’s leading sources of international travelers, China sees significant demand for yellow fever vaccinations, particularly among those visiting Africa and South America. Government efforts to expand access to travel health clinics and the integration of digital health platforms are supporting vaccine distribution. Additionally, the presence of strong domestic pharmaceutical manufacturers and increased investment in preventive healthcare services are key factors propelling the yellow fever market in China.

Yellow fever treatment Market Share

The yellow fever treatment industry is primarily led by well-established companies, including:

• Tychan Pte. Ltd. (Singapore)
• BIOCRYST PHARMACEUTICALS, INC. (United States)
• Sanofi (France)
• Merck & Co., Inc. (United States)
• CSL Limited (Australia)
• Johnson & Johnson Services, Inc. (United States)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Atom Medical Corp (Japan)
• Avihealthcare (India)
• GENERAL ELECTRIC COMPANY (United States)
• Ibis Medical (India)
• Natus Medical Incorporated (United States)
• Ningbo David Medical (China)
• Weyer GmbH (Germany)
• Signify Holding (Netherlands)
• Bayer AG (Germany)
• Pfizer Inc. (United States)
• Cleveland Clinic (United States)
• Bausch Health (Canada)
• Regeneron Pharmaceuticals, Inc. (United States)
• GlaxoSmithKline plc (United Kingdom)
• Bavarian Nordic AS (Denmark)
• Biological E Ltd (India)
• China National Pharmaceutical Group Corp (Sinopharm) (China)
• Codagenix Inc (United States)
• CureVac NV (Germany)
• Dultech Advanced Sciences (United States)
• Emergex Vaccines Holding Ltd (United Kingdom)
• Ennaid Therapeutics LLC (United States)

Latest Developments in Global Yellow fever treatment Market

• In September 2024, the yellow fever vaccine market was projected to grow from $4.32 billion in 2023 to USD 5.56 billion by 2028, at a CAGR of 5.2%. This growth reflects increased global travel, heightened awareness of yellow fever prevention, and the implementation of international health regulations requiring vaccination for entry into certain regions
• In 2024, Asia Pacific held a 23% share of the global yellow fever vaccine market, with India contributing USD 124.99 million and projected to grow at a CAGR of 9.3% through 2031. This growth is driven by increasing preventive healthcare initiatives and government immunization programs.
• In October 2023, the Bill & Melinda Gates Foundation announced a USD 40 million investment to help African manufacturers develop mRNA vaccines, including for diseases like yellow fever. This initiative aims to address vaccine inequity and build vaccine self-reliance in Africa
• In 2023, the World Health Organization (WHO) recommended that travelers obtain a valid international certificate of vaccination or prophylaxis (ICVP) as proof of yellow fever vaccination required for entry into certain countries. This recommendation underscores the importance of vaccination for international travel and public health safety
• In 2023, North America accounted for the largest share of the travel vaccines market, with yellow fever vaccines being a significant component. The region's high awareness of travel-related health risks and government initiatives to promote vaccinations contribute to this market dominance.

SKU-50408